Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure
Status:
Terminated
Trial end date:
2019-08-08
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well bosutinib works in treating patients with chronic
myeloid leukemia in chronic phase after frontline tyrosine kinase inhibitor (TKI) failure.
Bosutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell
growth.